A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Protein kinase CK2 is highly expressed in cancer cells.
• CK2 inhibition induces cancer cell apoptosis, making it a viable drug target.
• Existing CK2 inhibitors have limitations in clinical application.

Purpose of the Study:

• To develop and evaluate a novel biligand inhibitor targeting CK2.
• To assess the efficacy and selectivity of the inhibitor in cancer cells.
• To explore the potential of oligo-anionic biligand inhibitors in cancer therapy.

Main Methods:

• Synthesis of a biligand inhibitor (ARC-772) and its prodrug (ARC-775).
• In vitro kinase inhibition assays to determine binding affinity (K_d) and selectivity.
• Cell-based assays to measure apoptosis induction (caspase-3 activation) and EC₅₀ values.
• Platelet aggregation assays to assess off-target effects.

Main Results:

• ARC-772 demonstrated high binding affinity (K_d = 0.3 nm) and selectivity for CK2.
• ARC-775 showed efficient cellular uptake and activation by esterases.
• ARC-775 induced caspase-3 activation in HeLa cells at sub-micromolar concentrations (EC₅₀ = 0.3 μm), outperforming CX-4945.
• ARC-775 also inhibited ADP-induced platelet aggregation at micromolar concentrations.

Conclusions:

• Oligo-anionic biligand inhibitors represent a promising class of compounds for drug development.
• ARC-775 exhibits potent and selective CK2 inhibition with significant anti-cancer potential.
• The study highlights the therapeutic potential of novel CK2 inhibitors in cancer treatment.